The FDA's long-awaited approval for the transfemoral delivery of Edwards Lifesciences' (Irvine, California) Sapien transcatheter aortic heart valve is a fitting example of the old adage "good things come to those who wait." This represents the first artificial heart valve that can replace an aortic heart valve damaged by senile aortic valve stenosis without open-heart surgery, FDA noted.